ABIVAX Société Anonyme (NASDAQ:ABVX) Short Interest Update

ABIVAX Société Anonyme (NASDAQ:ABVX) was the target of a significant growth in short interest in the month of November. As of November 15th, there was short interest totalling 283,200 shares, a growth of 47.6% from the October 31st total of 191,900 shares. Based on an average trading volume of 122,700 shares, the days-to-cover ratio is presently 2.3 days. Currently, 0.5% of the company’s shares are sold short.

Institutional Investors Weigh In On ABIVAX Société Anonyme

Several large investors have recently bought and sold shares of ABVX. Janus Henderson Group PLC raised its holdings in shares of ABIVAX Société Anonyme by 18.2% during the first quarter. Janus Henderson Group PLC now owns 851,839 shares of the company’s stock worth $12,113,000 after acquiring an additional 131,414 shares during the period. Point72 Asset Management L.P. increased its position in shares of ABIVAX Société Anonyme by 28.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock worth $6,254,000 after purchasing an additional 119,300 shares during the last quarter. abrdn plc raised its stake in shares of ABIVAX Société Anonyme by 167.7% during the 3rd quarter. abrdn plc now owns 316,431 shares of the company’s stock worth $3,645,000 after purchasing an additional 198,225 shares in the last quarter. Walleye Capital LLC raised its position in ABIVAX Société Anonyme by 45.8% during the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock worth $2,965,000 after acquiring an additional 80,807 shares in the last quarter. Finally, Kennedy Capital Management LLC raised its holdings in shares of ABIVAX Société Anonyme by 35.3% in the 1st quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock valued at $1,718,000 after purchasing an additional 31,331 shares during the period. Institutional investors own 47.91% of the company’s stock.

ABIVAX Société Anonyme Trading Down 0.4 %

Shares of NASDAQ:ABVX opened at $8.53 on Friday. ABIVAX Société Anonyme has a one year low of $8.23 and a one year high of $17.02. The company has a 50 day moving average of $10.05 and a 200-day moving average of $11.77.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.